Introduction Leniolisib has emerged as a groundbreaking treatment for Apoptosis-Specific Precursor T-cell Immunodeficiency Syndrome (APDS), a rare genetic disorder that affects the immune system. This condition is characterised by recurrent infections, increased susceptibility to autoimmunity, and difficulty in responding to vaccines. The significance of leniolisib lies not only in its potential to improve the quality